Virtual ISPOR

Canada Grapples With Drug Price Escalation

May 21, 2020

Article

In July 2020 Canada will implement a series of reforms to help bring runaway drug prices under control, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.

Study Shows Variations in RWE Citation Frequency

May 20, 2020

Article

Real world evidence (RWE) was cited differently depending on a number of criteria, leaving the door open to future research on how RWE influences payer decision making for specialty drug plans, said presenting author, Ari Panzer, at the Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

ISPOR Panelists Weigh the Success of APMs

May 19, 2020

Article

The alternative payment model (APM) doesn’t perfectly balance the competing interests of revenue growth and value-based care, but it has been a learning tool, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.

Panelists Advocate for Global Collaboration in RWE Effort

May 19, 2020

Article

Harmonized efforts across global borders and among stakeholders are needed to generate and build acceptance of real world evidence (RWE) to actively aid in health care decision making, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.

International Reference Pricing Gets Thumbs-Down From ISPOR Panel

May 18, 2020

Article

There’s not enough study of the effects of international reference pricing, but it is likely to stifle innovation and create access problems, according to an expert panel at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.

What Can US Learn About Biosimilars From Europe?

May 24, 2019

Article

Europe has several lessons for the US biosimilar market, according to a pharmaceutical executive who spoke during ISPOR 2019.

Fresenius Kabi's Adalimumab Biosimilar Produces Comparable QOL Improvements to Humira

May 22, 2019

Article

Treatment with the biosimilar, the investigators concluded, resulted in comparable, maintained quality of life improvements that were not impacted by a switch from the reference product.

Biosimilar Monotherapy Sequence for RA Can Be Considered Cost-Effective, Study Finds

May 21, 2019

Article

Rheumatoid arthritis (RA) has a considerable economic burden, and costly biologics, are often restricted to cases in which patients fail to respond adequately to methotrexate or other conventional disease-modifying antirheumatic drugs, which may be difficult for some patients to tolerate.

Researchers Predict Substantial Savings for Europe on the Strength of Biosimilar Adalimumab

May 21, 2019

Article

During the ISPOR 2019 annual meeting, teams of investigators presented data estimating just how much healthcare systems could save by adopting biosimilar adalimumab for all indications of its reference in adult patients. The results highlighted both the scale of potential savings and the variability among European nations.

Health Plan Restrictions Likely to Have an Impact on Biosimilars, Orphan Drugs

May 20, 2019

Article

Despite their benefits to patients, innovative treatments, including biologics, come at a high cost to the healthcare system, and those in a position to make coverage decisions for these products must grapple with these therapies’ affordability. During the ISPOR 2019 meeting, researchers presented findings on how health plan restrictions could limit orphan drug coverage—and encourage biosimilar use—as a means to manage their budgets.

x